The Journal of Clinical Psychiatry · 1997 · 23 citations · 0 references
PharmacyPharmacotherapyPsychiatryClinical PharmacologyPsychiatric PharmacotherapyPsychopharmacologyAnxiety Disorder PharmacotherapyAnxiety DisordersAnxiolytic PharmacotherapyPanic DisorderPsychostimulant PharmacologyStimulant PharmacotherapyAgoraphobia TreatmentDropoutPanic Disorder TreatmentPanic Disorder With AgoraphobiaPanic Disorder Without AgoraphobiaPharmacological Anxiety ManagementPsychostimulant PharmacotherapyTreatment Of Anxiety Disorders
BACKGROUND: Controlled trials suggest that clomipramine may be a highly effective antipanic drug. Lowering the starting dose may alleviate troublesome initial side effects and increase acceptability and compliance. METHOD: Fifty-eight patients with DSM-III-R panic disorder with or without agoraphobia underwent 13 weeks of clomipramine treatment. Starting at 10 mg/day, the dose was gradually increased to a mean dose of 97 mg/day. RESULTS: While completers showed highly significant improvement, the benefits were severely limited by a high dropout rate due to adverse reactions occurring mostly during the first 2 weeks of treatment. CONCLUSION: Given the alternatives, clomipramine should not be used as a first-line antipanic medication.